Inmaculada Alonso-Abreu

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU

Inmaculada Alonso-Abreu, Laura Ramos, Alejandro Hernández-Camba, Carmen Yagüe-Caballero et autres

Background: Inflammatory bowel disease (IBD) and celiac disease (CeD) are immune-mediated digestive disorders with shared genetic, immunological, and environmental risk factors. Objectives: This study aimed to assess whether the coexistence of CeD and IBD is associated with a differential IBD disease course. …

es, in (code pays fourni par la source)

85 - OPTIMIZACIÓN FARMACOCINÉTICA PROACTIVA DEL TRATAMIENTO DE MANTENIMIENTO CON USTEKINUMAB EN PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL

Fabiola Pérez-González, Rashika Ashok Bhagchandani, Cristina Reygosa, Marta Carrillo-Palau et autres

Clinical, Endoscopic, and Histological Characteristics of Severe Immune Checkpoint Inhibitor-Induced Colitis

Diego Casas Deza, Cristina Polo Cuadro, Marta Gascón Ruiz, Manuel Barreiro-de Acosta et autres

Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. They can cause immune-mediated colitis (IMC), a potentially severe adverse event. Current data on severe IMC (grade 3–4) are limited, particularly regarding clinical, endoscopic, and histological features. Methods: We conducted a multicenter, retrospective …

es (code pays fourni par la source)

Natural history, immunological and genetic characteristics of preclinical inflammatory bowel disease (EARLY): study protocol for a prospective cohort study

Iago Rodríguez–Lago, Urko M. Marigorta, Beatriz Mateos, Míriam Mañosa et autres

Background: The period prior to the diagnosis of inflammatory bowel disease (IBD), defined as the preclinical phase, has emerged as a potential target for disease modification strategies. Despite the relevance of an early diagnosis to the prognosis of the disease, only a …

es (code pays fourni par la source)

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial

Antoni Castells, Enrique Quintero, Luís Bujanda, Susana Castán Cameo et autres

es, ch (code pays fourni par la source)

Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial

Antoni Castells Garangou, Enrique Quintero, Luis Bujanda, Susana Castán-Cameo et autres

P1227 Predictors of biologics/JAKi use, surgeries, and hospitalisations in a newly diagnosed cohort of IBD patients: Long-term outcomes from the nationwide EpidemIBD study of GETECCU

A Garre, Andrea Núñez Ortiz, S Rubio, M T Diz-Lois Palomares et autres

Abstract Background Factors influencing the exposure to targeted therapies (biologics/JAKi), intestinal resections and hospitalisations in newly diagnosed IBD patients have been scarcely studied. Aim: To identify predictive factors of exposure to biologics/JAKi, surgeries, and hospitalisations within the first five years in IBD …

es (code pays fourni par la source)

P0609 Real-world short and long-term effectiveness of risankizumab in refractory Crohn’s disease: RISANCROHN study from the ENEIDA Registry

M Barreiro-de Acosta, L Nieto-Garcia, M Poncela, Mariam Aguas et autres

Abstract Background Phase III trials have demonstrated the efficacy of risankizumab (RZB), this being the first humanized monoclonal IgG1 antibody which targets the interleukin 23 p19 subunit, in Crohn’s disease (CD). However, real-world data with this drug is limited. The aim of …

es (code pays fourni par la source)

P0226 Postoperative recurrence after a definitive ostomy in Crohn's disease. A nationwide retrospective series from the Eneida registry

M Calafat Sard, Míriam Mañosa, A Fernández-Clotet, Laura Pasanau et autres

Abstract Background Although the concept of postoperative recurrence (POR) in Crohn’s disease (CD) has been limited to patients undergoing intestinal resection with anastomosis, some small-sized retrospective series with short follow-up periods suggest that clinical POR may occur in up to 30% of …

es (code pays fourni par la source)

DOP103 Optimization of Ustekinumab Treatment Induction Using a Pharmacokinetic Model in Inflammatory Bowel Disease Patients

Laura Ramos López, Betel Del Rosario-García, Fabiola Pérez-González, Inmaculada Alonso-Abreu et autres

Abstract Background Therapeutic drug monitoring and pharmacokinetic modeling, implemented in the treatment of patients with inflammatory bowel disease (IBD), improve drug efficacy and reduce side effects. Recently, Ustekinumab (UST) levels associated with therapeutic targets have been established, principally during induction, highlighting the …

es (code pays fourni par la source)

FACTORES PREDICTORES DEL USO DE TRATAMIENTOS BIOLÓGICOS O PEQUEÑAS MOLÉCULAS, CIRUGÍAS Y HOSPITALIZACIONES EN UNA COHORTE DE PACIENTES RECIÉN DIAGNOSTICADOS DE EII: RESULTADOS A LARGO PLAZO DEL ESTUDIO EPIDEMIBD DE GETECCU

Andrea Núñez Ortiz, María Teresa Diz-Lois Palomares, Sabino Riestra, Horacio Alonso‐Galán et autres

P-46 - LA MONITORIZACIÓN DE NIVELES Y ANTICUERPOS DE INFLIXIMAB PREDICEN SU EFICACIA INDEPENDIENTEMENTE DE HLA-DQA1*05

Inmaculada Alonso-Abreu, Belén del Valle Vera, Milagros Vela, Andrea Morant et autres